Toripalimab Combo Improves Survival Vs Sunitinib in Renal Cell Carcinoma

Article

In the phase 3 RENOTORCH trial, frontline toripalimab plus axitinib appears to improve the overall response rate of patients with unresectable or metastatic renal cell carcinoma.

The frontline use of toripalimab (Tuoyi) in combination with axitinib (Inlyta) to treat patients with advanced renal cell carcinoma (RCC) has proven efficacious and met the primary end point of progression-free survival (PFS) in the phase 3 RENOTORCH trial (NCT04394975), according to a press release from Shanghai Junshi Biosciences.

Investigators will present detailed findings from the phase 3 RENOTOCH study at a future international medical conference.

Investigators will present detailed findings from the phase 3 RENOTOCH study at a future international medical conference.

These results came from a prespecified interim analysis, which found that the toripalimab regimen yielded a significant reduction in the risk of disease progression or death compared with sunitinib (Sutent) monotherapy. The Independent Data Monitoring Committee (IDMC) thus determined that the primary end point of PFS had met its predefined efficacy boundary.

Toripalimab also produced an improved overall response rate (ORR), a secondary end point. The safety profile of the agent was consistent with its known risks; no new safety signals were identified. Investigators will release detailed findings from the study at a future international medical conference.

“Thanks to the collective efforts of the investigators, patients, [research and development] teams and many others, the RENOTORCH study has been a great success,” Jianjun Zou, MD, president of global research and development at Junshi Biosciences, said in the press release. “We believe that RENOTORCH’s positive results will help bridge the gap in renal cancer PD-L1 immunotherapy in China, and we will take all the necessary steps to commercialize this achievement and provide new and effective combination immunotherapy options for domestic patients.”

Toripalimab is an anti-PD-1 monoclonal antibody designed to impede the interactions between PD-1 and its ligands, PD-L1 and PD-L2, which promotes the immune system’s ability to eliminate tumor cells. The agent is also designed to enhance receptor internalization.

The multicenter, randomized, open-label phase 3 RENOTORCH study enrolled 421 patients across 47 Chinese medical centers. This study population consisted of patients with intermediate- to high-risk unresectable or metastatic RCC.

The trial randomly assigned patients 1:1 to receive 240 mg of toripalimab intravenously every 3 weeks in combination with 5 mg of axitinib orally twice a day or 50 mg of sunitinib orally once a day until disease progression or unacceptable toxicity.

The primary end point was PFS as assessed by an Independent Radiographic Review Committee (IRC). Secondary end points included investigator-assessed PFS, IRC- or investigator-assessed ORR, duration of response, disease control rate, overall survival, and toxicity.

To be eligible for inclusion, patients must have received no prior systemic therapy after previous metastasis for RCC. An ECOG performance status of 0 or 1, along with adequate bone marrow, renal, hepatic, endocrine, and coagulation function, were among the other inclusion criteria.

Exclusion criteria included any prior treatment with agents targeting PD-1, PD-L1, or CTLA-4, as well as any prior systemic anti-cancer therapy following metastasis. Patients were also excluded if they experienced progression or recurrence either during adjuvant or neoadjuvant therapy for RCC within 12 months after the last dose of treatment. Another exclusion criterion was any additional malignancy that had progressed or necessitated treatment in the 5 years prior to randomization, with the exceptions of basal or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ for which the patient has received potentially curative therapy.

Reference

Junshi Biosciences announces primary endpoint met in RENOTORCH study of toripalimab for 1st-line treatment of advanced renal cell carcinoma. News Release. Shanghai Junshi Biosciences Co., Ltd. April 27, 2023. Accessed April 27, 2023. https://bit.ly/3oRVtEP

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content